Pages that link to "Q36467864"

The following pages link to Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry (Q36467864):

Displaying 18 items.

• Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents (Q34265621) (← links)
• Chemotherapy of advanced breast cancer: outcome and prognostic factors (Q35977908) (← links)
• The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents (Q36126057) (← links)
• Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer (Q36136402) (← links)
• FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial (Q36286955) (← links)
• Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations? (Q36292270) (← links)
• Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90) (Q36292466) (← links)
• Dose adaptation of antineoplastic drugs in patients with liver disease (Q36497053) (← links)
• Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents (Q38546964) (← links)
• Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy (Q40488017) (← links)
• Anthracyclines in haematology: pharmacokinetics and clinical studies (Q40858576) (← links)
• Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme (Q44357042) (← links)
• Chemotherapy during pregnancy: what is really safe? (Q44961610) (← links)
• Weekly epirubicin in the treatment of gestational breast cancer (GBC). (Q46422822) (← links)
• Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies (Q51613418) (← links)
• Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry: Initial weekly treatment followed by rescheduling and intensification (Q67760102) (← links)
• Breast cancer and liver metastases--incidence, diagnosis and outcome (Q67908718) (← links)
• Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients (Q90211749) (← links)